TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast~* Participants must have undergone sentinel lymph node mapping or axillary dissection~* Participants must have had a pre-operative Perometer measurement, and consecutive measurement at 4-6 month intervals prior to the onset of low volume edema (\>5% from baseline)~* Age \> 18 years~* Life expectancy of greater than 1 year~* Participants must have a Perometer measurement of 5% or greater volume difference (RVC) to qualify for randomization~* Ability to understand and willingness to sign a written informed consent document~* Willingness to comply with required follow up Perometer measurements and clinical visits~Exclusion Criteria:~* Known metastatic disease or other locally advanced disease in the thoracic or cervical regions~* Any patient who will not be returning routinely for follow-up~* Known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events~* History of primary lymphedema~* History of prior surgery or radiation to the head, neck, upper limb, or trunk~* Evidence that axillary lymph node malignancy is causing lymphedema due to recurrence as per physician discretion~* Any patient who has bilateral lymph node mapping or dissection~* Any patient with a current case of cellulitis~* Patients with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancer are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1A (Type: NO_INTERVENTION): Mild Lymphedema: Only required to meet with the lymphedema physical therapist
- Group 1B (Type: ACTIVE_COMPARATOR): Mild Lymphedema: Fitted for compression sleeve
- Group 2A (Type: ACTIVE_COMPARATOR): Moderate lymphedema: Fitted with a compression sleeve
- Group 2B (Type: ACTIVE_COMPARATOR): Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dry Needling and Functional Improvement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* presence of at least one painful trigger point in the gluteals (gluteus maximus or medius) and infraspinatus on the same side.~Exclusion Criteria:~* neurologic conditions (neuropathy, myopathy)~* use of medication (antidepressants, opioids) and/or acute cervico-thoracic injury (whiplash, facet irritation, acute discopathy) that could directly influence normal somatosensory processing at the C5 segment \[Srbely\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dry Needling (Type: EXPERIMENTAL): Trigger points found in the gluteal region of one side (e.g. right) will be dry needled; presence of muscle twitching (which would signify appropriate needle insertion) will be documented.
- Sham Dry Needling (Type: SHAM_COMPARATOR): Trigger points found in the gluteal region of one side (e.g. right) will be SHAM dry needled with blunted needles, no actual penetration through the skin will occur.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Therapy of GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. First allogeneic hematopoietic cell transplantation (second transplants are rare, typically performed for relapse of leukemia, in which case the likelihood of relapse is high, and there is the theoretical risk of increasing the likelihood further with ATG).~2. Conditioning including ATG 4.5 mg/kg (the predictive value of IL15 and IL2Ra levels was determined in patients whose conditioning included 4.5 mg/kg or ATG).~3. Age \>17 (the predictive value of IL15 and IL2Ra levels has not been studied in children).~Exclusion Criteria:~1. Nonmyeloablative conditioning (possible risk of ATG increasing relapse).~2. Active viral infection (risk of worsening of the viral infection with ATG).~3. Neutropenic fever with hypotension. In such case, the ATG can be given on day 9 (instead of day 8) if patient no longer has hypotension.~4. Hypoxemia. In such case, the ATG can be given on day 9 (instead of day 8) if patient no longer has hypoxemia.~5. History of anaphylactic reaction to Thymoglobulin or another rabbit blood protein.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stage 2 infection with Trypanosoma brucei gambiense diagnosed within the previous 14 days, as defined by either of the following: (i) Presence of trypanosomes in blood or lymph node fluid and WBC count in CSF \> 5 / mm3, or (ii) Presence of trypanosomes in the CSF with any CSF WBC count~* Residence in the study area~* Written informed consent (to be obtained from parent/guardian for children under 18 years and patients with impaired cognition)~Exclusion Criteria:~* Pregnancy or clinical history suggestive thereof~* Weight \< 10 Kg~* History of any HAT treatment within the previous 24 months~* Inability to undergo hospitalisation or attend follow-up visits during the 24 months following discharge~* Severe anemia (Hb\< 5g/dl)~* Active tuberculosis (sputum positive)~* HIV positive (if patient has been tested and results are known)~* Severe renal or hepatic failure~* Bacterial or cryptococcal meningitis~* Other severe underlying diseases upon admission~* Refugee status

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adherence to Antidepressant Treatment in Subjects With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline QIDS-SR ≥ 14 (moderate depression)~* Age 18 - 65~* Written Informed Consent~* Major Depressive Disorder, single-episode/recurrent, not in remission~Exclusion Criteria:~* RT2CK17-related exclusions~* Uncontrolled hyperthyroidism~* Glaucoma~* Motor tics~* Monoamine oxidase inhibitor treatment~* Serious coronary artery disease, cardiomyopathy, serious cardiac arrhythmias~* Uncontrolled hypertension~* Peripheral vasculopathy~* Pregnancy~* Bipolar Disorder~* Psychotic Disorder~* History of intolerability of study medications~* Currently taking psychiatric medications~* Current Substance Use Disorder (other than nicotine)~* Current Alcohol Use Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram + RT2CK17 (Type: ACTIVE_COMPARATOR): 10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
- Escitalopram + Placebo (Type: PLACEBO_COMPARATOR): 10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Feedback on Blood Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>= 18 years old undergoing total hip arthroplasty or hip hemiarthroplasty~Exclusion Criteria:~* Refusal of blood transfusions~* Surgeons utilizing fast track protocols (planned discharge on postoperative day 1 or 2 following surgery.)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Feedback Arm (Type: EXPERIMENTAL): Orthopedic surgeons in the Feedback Arm will receive monthly reports providing individualized data on compliance with the FOCUS trial RBC transfusion guideline (pretransfusion Hb \<8 g/dL for hip surgery patients in the postoperative period.) Feedback data will be anonymized, but surgeons will be able to see their own data in comparison with their peers.
- Control Arm (Type: NO_INTERVENTION): Orthopedic surgeons in the Control Arm will not receive any feedback on their use of RBC transfusion in hip surgery patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient who is eligible for definitive curative radio-chemotherapy with Cisplatin or radio-immunotherapy with Cetuximab.~* Written informed consent obtained prior to any study specific screening activities and patients have to be able to comply with this protocol.~* Histologically confirmed local advanced squamous cell carcinoma of the Larynx, Hypopharynx, Oropharynx or Cavum oris treated with definitive radiotherapy in combination with Cisplatin or Cetuximab.~* p16 status available~* Age ≥ 18~* Women of childbearing potential must have a negative pregnancy test at screening and must use effective contraception.~Exclusion Criteria:~* Distant metastases~* Prior radiation (Head and neck area)~* Pregnant or lactating women~* History of other malignancy; yet patients who have been disease-free for 5 years or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* Concurrent other cancer therapy (chemotherapy, immunotherapy, antihormonal or biologic therapy) or concurrent treatment with an investigational drug.~* Serious medical or psychiatric disorders that would interfere with the patient's safety or informed consent.~* Participation in another interventional clinical study at time of study inclusion (except follow-up period without treatment for more than 30 days) or denial of the simultaneous participation in a non-interventional study by the PI of the study center.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A - Standard of care (Type: ACTIVE_COMPARATOR): Standard care of parenteral nutrition (with or without parenteral nutrition during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin
- Arm B - Parenteral over night nutrition (Type: EXPERIMENTAL): Parenteral over night nutrition with ZentroOLIMEL 5.7% parenteral over night with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) 15 ml/kg body weight/day (weight loss \>5% from baseline; parenteral nutrition increased up to 25 ml/kg body weight per day) during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with diffuse large B-cell lymphoma according to the WHO classification (anti CD20 labeling)~* Aged from 60 to 65 years.~* Not previously treated.~* Ann Arbor stage II, III, IV.~* ECOG performance status 0 to 2.~* Minimum life expectancy of 3 months.~* Negative HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies test 4 weeks (except after vaccination).~* Having previously signed a written informed consent.~Exclusion Criteria:~* T-cell lymphoma.~* Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.~* Central nervous system or meningeal involvement by lymphoma.~* Contra-indication to any drug contained in the chemotherapy regimens.~* Any serious active disease (according to the investigator's decision).~* Poor renal function (creatinine level\>150micromol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor bone marrow reserve as defined by neutrophils\<1.5G/l or platelets\<100G/l, unless related to bone marrow infiltration.~* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~* Adult patient under tutelage.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- R-ACVBP (Type: EXPERIMENTAL): Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
- R-CHOP (Type: ACTIVE_COMPARATOR): Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with bipolar disorder in major depressive episode according to DSM-IV~* MADRS score of at least 20 points at screening and baseline~* 18-70 years of age~* Unchanged dose of mood stabilising medication for at least six weeks prior to inclusion~* Voluntary, informed and written consent~Exclusion Criteria:~* Non-affective psychotic symptoms at screening~* Pregnancy or breast-feeding~* Fertile women without appropriate contraception (the pill, IUD, or contraceptive injection)~* Substance dependence during the last three months prior to baseline~* Mental retardation and organic brain disorders~* Suicide risk that mandates specific measures~* Novel (within three months) or unstable medical conditions~* Clinically significant abnormal results on medical examination or blood samples~* Exposure to escitalopram during the last three months~* Allergic reactions to citalopram or escitalopram~* Anorexia nervosa with body mass index below 18~* Formal psychotherapy started within six weeks of screening~* Electroconvulsive therapy (ECT) during the current episode of depression~* Patients who are unlikely to be reliable and compliant with study procedures~* Patients who are not fluent in Norwegian

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Randomized Study Evaluating The Efficacy of Chlorhexidine Gluconate Impregnated No-Rinse Cloths.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Joint replacement surgery for any reason~* 18 years or older~Exclusion Criteria:~* unable to comply with study requirements~* were pregnant~* were under the age of 18 years~* medical history of immunosuppression or systemic disease e.g. human immunodeficiency virus, status-post organ transplantation~* received greater than 10 milligrams of prednisone equivalent for more than 10 days within 90 days prior to enrollment;~* chronic hepatitis B or C infection~* had an infection in or around the joint requiring surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primary Control TKA (Type: SHAM_COMPARATOR): Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
- Primary Treatment TKA (Type: ACTIVE_COMPARATOR): Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
- Revision Treatment TKA (Type: ACTIVE_COMPARATOR): Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of a chlorhexidine impregnated cloths.
- Revision Control TKA (Type: SHAM_COMPARATOR): Patients undergoing a second or revision total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
- Primary Control THA (Type: SHAM_COMPARATOR): Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
- Primary Treatment THA (Type: ACTIVE_COMPARATOR): Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
- Revision Control THA (Type: SHAM_COMPARATOR): Patients undergoing a second or revision total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
- Revision Treatment THA (Type: ACTIVE_COMPARATOR): Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute symptomatic ischemic stroke having relevant lesion on DWI(Diffusion weighted image) MRI 7 days after and 42 days within onset.~* relevant stenosis(more than 50%) or occlusion from MCA(middle cerebral artery)(M1) to distal of ICA(internal carotid artery ) on MR(Magnetic resonance) angiogram or CT angiogram.~* mean systolic blood pressure\>=140mmHg or taking antihypertensive drug on screening.~Exclusion Criteria:~* taking more than 3 antihypertensive drugs and mean systolic blood pressure\>=150mmHg on screening.~* history of recent thrombolysis but stenosis or occlusion remained after thrombolysis.~* evidence of orthostatic hypotension~* suspicious embolic cerebrovascular stenosis~* planned state of cerebrovascular surgery or angioplasty or stent 7 months within screening.~* severe stroke-NIHSS\>=16~* mean systolic blood pressure\>=200mmHg which is not able to control on screening.~* abnormal blood test finding (abnormal LFT(liver function test), anemia, renal insufficiency)~* pregnant or breast-feeding~* severe stroke sequela or medical problem~* suspicious secondary hypertension~* disease causing edema or significant ankle edema on screening.~* severe heart failure which correspond to NYHA (New York Heart Association )heart failure classification class III or IV.~* inappropriate condition determined by investigator~* Patient who do not have FLAIR image on or two months prior to screening.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aggressive BP lowering (Type: EXPERIMENTAL): Lowering of systolic blood pressure between 110mmHg and 120mmHg during study period
- Modest BP lowering (Type: ACTIVE_COMPARATOR): Lowering of systolic blood pressure between 130mmHg and 140mmHg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility